Co-Authors
This is a "connection" page, showing publications co-authored by Andrew Aplin and Inna Chervoneva.
Connection Strength
2.906
-
Rosenbaum SR, Tiago M, Caksa S, Capparelli C, Purwin TJ, Kumar G, Glasheen M, Pomante D, Kotas D, Chervoneva I, Aplin AE. SOX10 requirement for melanoma tumor growth is due, in part, to immune-mediated effects. Cell Rep. 2021 12 07; 37(10):110085.
Score: 0.246
-
Teh JLF, Erkes DA, Cheng PF, Tiago M, Wilski NA, Field CO, Chervoneva I, Levesque MP, Xu X, Dummer R, Aplin AE. Activation of CD8+ T Cells Contributes to Antitumor Effects of CDK4/6 Inhibitors plus MEK Inhibitors. Cancer Immunol Res. 2020 Sep; 8(9):1114-1121.
Score: 0.223
-
Nguyen MQ, Teh JLF, Purwin TJ, Chervoneva I, Davies MA, Nathanson KL, Cheng PF, Levesque MP, Dummer R, Aplin AE. Targeting PHGDH upregulation reduces glutathione levels and re-sensitizes resistant NRAS mutant melanoma to MEK inhibition. J Invest Dermatol. 2020 May 07.
Score: 0.220
-
Rosenbaum SR, Knecht M, Mollaee M, Zhong Z, Erkes DA, McCue PA, Chervoneva I, Berger AC, Lo JA, Fisher DE, Gershenwald JE, Davies MA, Purwin TJ, Aplin AE. FOXD3 Regulates VISTA Expression in Melanoma. Cell Rep. 2020 Jan 14; 30(2):510-524.e6.
Score: 0.215
-
Erkes DA, Rosenbaum SR, Field CO, Chervoneva I, Villanueva J, Aplin AE. PLX3397 inhibits the accumulation of intra-tumoral macrophages and improves BET inhibitor efficacy in melanoma. Pigment Cell Melanoma Res. 2019 Nov 06.
Score: 0.212
-
Sanchez IM, Purwin TJ, Chervoneva I, Erkes DA, Nguyen MQ, Davies MA, Nathanson KL, Kemper K, Peeper DS, Aplin AE. In vivo ERK1/2 reporter predictively models response and resistance to combined BRAF and MEK inhibitors in melanoma. Mol Cancer Ther. 2019 Jul 03.
Score: 0.207
-
Erkes DA, Field CO, Capparelli C, Tiago M, Purwin TJ, Chervoneva I, Berger AC, Hartsough EJ, Villanueva J, Aplin AE. The next generation BET inhibitor, PLX51107, delays melanoma growth in a CD8-mediated manner. Pigment Cell Melanoma Res. 2019 May 07.
Score: 0.205
-
Hartsough EJ, Weiss MB, Heilman SA, Purwin TJ, Kugel CH, Rosenbaum SR, Erkes DA, Tiago M, HooKim K, Chervoneva I, Aplin AE. CADM1 is a TWIST1-regulated suppressor of invasion and survival. Cell Death Dis. 2019 Mar 25; 10(4):281.
Score: 0.204
-
Nikbakht N, Tiago M, Erkes DA, Chervoneva I, Aplin AE. BET inhibition modifies melanoma infiltrating T cells and enhances response to PD-L1 blockade. J Invest Dermatol. 2019 Jan 28.
Score: 0.201
-
Teh JLF, Cheng PF, Purwin TJ, Nikbakht N, Patel P, Chervoneva I, Ertel A, Fortina PM, Kleiber I, HooKim K, Davies MA, Kwong LN, Levesque MP, Dummer R, Aplin AE. Correction: In Vivo E2F Reporting Reveals Efficacious Schedules of MEK1/2-CDK4/6 Targeting and mTOR-S6 Resistance Mechanisms. Cancer Discov. 2018 Dec; 8(12):1654.
Score: 0.199
-
Capparelli C, Purwin TJ, Heilman SA, Chervoneva I, McCue PA, Berger AC, Davies MA, Gershenwald JE, Krepler C, Aplin AE. ErbB3 Targeting Enhances the Effects of MEK Inhibitor in Wild-Type BRAF/NRAS Melanoma. Cancer Res. 2018 Oct 01; 78(19):5680-5693.
Score: 0.195
-
Teh JLF, Cheng PF, Purwin TJ, Nikbakht N, Patel P, Chervoneva I, Ertel A, Fortina PM, Kleiber I, HooKim K, Davies MA, Kwong LN, Levesque MP, Dummer R, Aplin AE. In vivo E2F reporting reveals efficacious schedules of MEK1/2-CDK4/6 targeting and mTOR-S6 resistance mechanisms. Cancer Discov. 2018 Mar 01.
Score: 0.189
-
Teh JL, Purwin TJ, Greenawalt EJ, Chervoneva I, Goldberg A, Davies MA, Aplin AE. An In Vivo Reporter to Quantitatively and Temporally Analyze the Effects of CDK4/6 Inhibitor-Based Therapies in Melanoma. Cancer Res. 2016 Sep 15; 76(18):5455-66.
Score: 0.170
-
Capparelli C, Rosenbaum S, Berman-Booty LD, Salhi A, Gaborit N, Zhan T, Chervoneva I, Roszik J, Woodman SE, Davies MA, Setiady YY, Osman I, Yarden Y, Aplin AE. ErbB3-ErbB2 Complexes as a Therapeutic Target in a Subset of Wild-type BRAF/NRAS Cutaneous Melanomas. Cancer Res. 2015 Sep 1; 75(17):3554-67.
Score: 0.158
-
Terai M, Shimada A, Chervoneva I, Hulse L, Danielson M, Swensen J, Orloff M, Wedegaertner PB, Benovic JL, Aplin AE, Sato T. Prognostic Values of G-Protein Mutations in Metastatic Uveal Melanoma. Cancers (Basel). 2021 Nov 17; 13(22).
Score: 0.061